Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.

Intuitive Surgical remains a wide-moat leader in robotic surgery with strong secular tailwinds and high recurring revenue potential. ISRG's installed base and utilization rates offer significant runway for growth, supported by product innovation and expansion into new markets. Despite a compression in valuation multiples, ISRG's forward P/E remains attractive given its historical premium and robust growth prospects.

GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.

These companies haven't said their last words.

Intuitive Surgical, Inc. remains a Buy, with strong recurring revenue, robust cash generation, and a market-leading position in robotic surgery despite recent share price weakness. Q3 expectations reflect slower procedure growth and affordability pressures, but ISRG's installed base, da Vinci 5 upgrade cycle, and SP/Ion adoption underpin long-term growth. Margins are expected to peak this year, aided by extended use programs that lower system costs and potentially increase competitive barriers.

Intuitive Surgical sees strong growth in India and improving conditions in Japan helping offset China headwinds as international da Vinci procedures rise 20%.

Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, and nutrition. Intuitive Surgical maintains a dominant lead in robotic-assisted surgery with high recurring revenue from instruments and services.

Twenty-four of 32 analysts covering Intuitive Surgical rate the stock as a "buy" or "strong buy." However, Intuitive faces multiple headwinds that are pressuring its growth.

Tesla Inc's (NASDAQ:TSLA) Optimus is built around the biggest ambition in robotics: a general-purpose humanoid that can handle a wide range of physical tasks. But the bigger investment opportunity may not require a robot that does everything.

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).